# Unmasking small-bowel DLBCL in an elderly patient with simultaneous multiple primary cancers through anemia: a case report and literature review

**Authors:** Binlin Da, Chen Zhao, Yao Yao, Chengting Dai, Nan Zhu, Wei Yan, Juanjuan Zhang, Jun Jiang, Zhiming Wang, Lei Guo

PMC · DOI: 10.3389/fonc.2026.1706363 · Frontiers in Oncology · 2026-02-19

## TL;DR

An elderly man with a history of cancer developed a rare lymphoma in his small intestine, diagnosed through anemia and imaging, highlighting the need to consider new cancers in cancer survivors.

## Contribution

This case report emphasizes the importance of considering metachronous hematologic malignancies in cancer survivors with atypical symptoms.

## Key findings

- A 71-year-old male with prior cardia and lung cancers developed primary small intestinal DLBCL nine years later.
- Anemia and imaging led to the diagnosis of small-bowel lymphoma, confirmed by biopsy and PET-CT.
- The case underscores the diagnostic challenge of new malignancies in cancer survivors with non-specific symptoms.

## Abstract

Multiple primary cancers (MPC) refer to the occurrence of two or more histologically distinct tumor types in a single individual, either simultaneously or sequentially. This report presents a rare and instructive case of a 71-year-old male who developed primary small intestinal diffuse large B-cell lymphoma (DLBCL) nine years after curative treatment for synchronous cardia and lung adenocarcinomas. The patient presented with dizziness and fatigue. Initial evaluation at a local hospital revealed moderate anemia (hemoglobin 66 g/L). Esophagogastroduodenoscopy and colonoscopy showed no remarkable findings. Subsequently, capsule endoscopy was performed. The capsule endoscopy demonstrated a segment of abnormal small bowel mucosa, showing marked edema, extensive erosions, and deep ulcers. The patient was then admitted to our center for further diagnosis and treatment. Chest computed tomography (CT) demonstrated postoperative changes from the prior lung and cardia cancers. Contrast-enhanced abdominal CT revealed focal ileal wall thickening and multiple small lymph nodes, suggestive of a neoplastic lesion. Further investigation was recommended. Single-balloon enteroscopy revealed a circumferential neoplastic growth, approximately 10 cm in length, with an ulcerative appearance and a dirty purulent coating in the ileum. Biopsy of the ileal lesion revealed a malignant lymphohematopoietic tumor with ulceration and necrosis, which on immunohistochemistry supported a diagnosis of aggressive B-cell lymphoma. Then the patient completed positron emission tomography - computed tomography (PET-CT) showing primary small-bowel lymphoma, Lugano staging 1E. To alleviate anemia and reduce the tumor burden, a partial resection of the ileum was performed. The segmental ileal resection confirmed DLBCL. Postoperatively, the patient was advised to be transferred to the oncology department for R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemoimmunotherapy. This case highlights the diagnostic challenge of evaluating new symptoms in cancer survivors and underscores the critical importance of considering metachronous hematologic malignancies, even with atypical presentations like isolated anemia, to avoid anchoring bias towards prior solid tumors.

## Linked entities

- **Chemicals:** cyclophosphamide (PubChem CID 2907), doxorubicin (PubChem CID 31703), vincristine (PubChem CID 5978), prednisone (PubChem CID 5865)
- **Diseases:** diffuse large B-cell lymphoma (MONDO:0018905), adenocarcinoma (MONDO:0004970), anemia (MONDO:0002280)

## Full-text entities

- **Genes:** TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, TIA1 (TIA1 cytotoxic granule associated RNA binding protein) [NCBI Gene 7072] {aka ALS26, TIA-1, WDM}, CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}, SPN (sialophorin) [NCBI Gene 6693] {aka CD43, GALGP, GPL115, LEU-22, LSN}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, SYNM (synemin) [NCBI Gene 23336] {aka DMN, SYN}, TRB (T cell receptor beta locus) [NCBI Gene 6957] {aka TCRB, TRB@}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, SMARCB1 (SWI/SNF related BAF chromatin remodeling complex subunit B1) [NCBI Gene 6598] {aka BAF47, CSS3, INI-1, INI1, MRD15, PPP1R144}, IGH (immunoglobulin heavy locus) [NCBI Gene 3492] {aka IGD1, IGH.1@, IGH@, IGHD@, IGHDY1, IGHJ}, PWWP3A (PWWP domain containing 3A, DNA repair factor) [NCBI Gene 84939] {aka EXPAND1, HSPC211, MUM-1, MUM1}, SMARCA4 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4) [NCBI Gene 6597] {aka BAF190, BAF190A, BRG1, CSS4, MRD16, OTSC12}, SLPI (secretory leukocyte peptidase inhibitor) [NCBI Gene 6590] {aka ALK1, ALP, BLPI, HUSI, HUSI-1, HUSI-I}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TRDD3 (T cell receptor delta diversity 3) [NCBI Gene 28523] {aka TCRD}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, IGK (immunoglobulin kappa locus) [NCBI Gene 50802] {aka IGK@}, CHGA (chromogranin A) [NCBI Gene 1113] {aka CGA, PHE5, PHES}, TRGC1 (T cell receptor gamma constant 1) [NCBI Gene 6966] {aka C1, TCRG, TCRGC1}
- **Diseases:** Epstein-Barr virus (MESH:D020031), prostate cancer (MESH:D011471), rheumatoid arthritis (MESH:D001172), metastasis (MESH:D009362), ascites (MESH:D001201), anemia (MESH:D000740), bowel obstruction (MESH:D012778), FL (MESH:D008224), Primary small bowel lymphoma (MESH:D015451), hepatomegaly (MESH:D006529), viral infections (MESH:D014777), colorectal cancer (MESH:D015179), intussusception (MESH:D007443), pain (MESH:D010146), cytopenias (MESH:D006402), immune impairments (MESH:D020274), carcinogenic (MESH:D011230), bone marrow infiltration (MESH:D001855), immune deficiency (MESH:D007154), adenocarcinoma (MESH:D000230), primary (MESH:D010538), cancers (MESH:D009369), Sjogren's syndrome (MESH:D012859), Crohn's Disease (MESH:D003424), aneurysmal dilation (MESH:D002311), left upper lobe lung cancer (MESH:D008175), ulcerative (MESH:D014456), anorexia (MESH:D000855), edema (MESH:D004487), dizziness (MESH:D004244), MALT (MESH:D018442), erosions (MESH:D014077), weight loss (MESH:D015431), abdominal pain (MESH:D015746), intra (MESH:D057072), autoimmune diseases (MESH:D001327), B-cell lymphoma (MESH:D016393), Gastric cancer (MESH:D013274), bleeding (MESH:D006470), cardia and lung adenocarcinoma (MESH:D000077192), obesity (MESH:D009765), breast cancer (MESH:D001943), splenomegaly (MESH:D013163), Lymphoma (MESH:D008223), NHL (MESH:D008228), gastrointestinal tumors (MESH:D005770), fatigue (MESH:D005221), HL (MESH:D006689), perforation (MESH:D057112), BL (MESH:D002051), sarcoma (MESH:D012509), Hematological malignancies (MESH:D019337), IE (MESH:C566577), necrosis (MESH:D009336), MCL (MESH:D020522), immune dysregulation (OMIM:614878), Diffuse large B-cell lymphoma (MESH:D016403), chronic immune deficiency (MESH:D015673), ileal lesion (MESH:D007077), invasive (MESH:D009361)
- **Chemicals:** R-CHOP (-), PI (MESH:D010716), 18F-fluorodeoxyglucose (MESH:D019788)
- **Species:** Human immunodeficiency virus (species) [taxon 12721], hepatitis C virus [taxon 11103], Homo sapiens (human, species) [taxon 9606], Hepatitis B virus (no rank) [taxon 10407]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960075/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960075/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960075/full.md

---
Source: https://tomesphere.com/paper/PMC12960075